Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/09/24
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and BayerZacks Investment Research • 10/08/24
Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching24/7 Wall Street • 10/07/24
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trialBusiness Wire • 10/07/24
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asthma patientsGlobeNewsWire • 10/07/24
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded UseZacks Investment Research • 10/03/24
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphomaBusiness Wire • 10/03/24
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell CarcinomaBusiness Wire • 10/02/24
Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast CancerBusiness Wire • 10/02/24
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded UseZacks Investment Research • 10/01/24
AstraZeneca PLC (AZN) Annual Deutsche Bank Leveraged Finance Conference (Transcript)Seeking Alpha • 09/24/24